^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sotevtamab (AB-16B5)

    i
    Other names: AB-16B5, AB16B5, Anti-Human CLU Therapeutic Antibody, anti-clusterin antibody
    Associations

    News

    Trials
    Company:
    Alethia BioTherap
    Drug class:
    Clusterin inhibitor, EMT inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    EGIA-003: Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (clinicaltrials.gov)
    P2, N=17, Recruiting, Alethia Biotherapeutics | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • sotevtamab (AB-16B5)
    almost2years
    EGIA-003: Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (clinicaltrials.gov)
    P2, N=17, Recruiting, Alethia Biotherapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • sotevtamab (AB-16B5)
    2years
    EGIA-003: Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (clinicaltrials.gov)
    P2, N=17, Not yet recruiting, Alethia Biotherapeutics
    New P2 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • sotevtamab (AB-16B5)
    2years
    AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov)
    P2, N=35, Completed, Alethia Biotherapeutics | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    docetaxel • sotevtamab (AB-16B5)
    over2years
    AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Alethia Biotherapeutics | Trial primary completion date: Mar 2023 --> Dec 2023
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    docetaxel • sotevtamab (AB-16B5)
    over3years
    AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Alethia Biotherapeutics | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    docetaxel • sotevtamab (AB-16B5)
    over3years
    AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov)
    P2, N=40, Recruiting, Alethia Biotherapeutics | Trial completion date: Jul 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    docetaxel • sotevtamab (AB-16B5)
    almost5years
    AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov)
    P2, N=40, Recruiting, Alethia Biotherapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    docetaxel • sotevtamab (AB-16B5)